Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2024, representing a year-on-year increase of 15%[14]. - The company's operating revenue for the first half of the year was approximately CNY 300.48 million, representing a 2.92% increase compared to the same period last year[19]. - The total revenue for the reporting period was 604.5 million RMB, with a net profit of 122.36 million RMB, indicating a strong financial performance[52]. - The company achieved a revenue of 300.48 million yuan, representing a year-on-year growth of 2.92%[62]. - The company reported a significant performance decline, with a reduction in revenue by 20% year-over-year[115]. - The company reported a net loss of CNY 125,548,761.89 for the current period, compared to a net loss of CNY 84,417,293.52 in the previous period, indicating a worsening financial performance[186]. User Engagement and Market Expansion - User data indicates that the active user base has grown to 1.5 million, up 20% compared to the same period last year[14]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[14]. - The company is expanding its market presence in Asia, targeting a 30% increase in market share by the end of 2025[116]. - User data showed a growth of 30% in active users year-over-year, reaching 1.5 million users[118]. Research and Development - Research and development expenses increased by 30% to RMB 15 million, focusing on innovative healthcare solutions and technology advancements[14]. - The company has a strong focus on R&D, integrating traditional software technology with new-generation information technology to enhance its product offerings[33]. - The company applied for 26 new invention patents and obtained 6 invention patent authorizations during the reporting period, bringing the total number of authorized invention patents to 51[39]. - The company has developed six core technologies for specialized electronic medical records, enhancing data usability and precision in medical decision-making[56]. - The company has made significant investments in R&D for smart clinical, smart management, and medical AI technologies[63]. Technology and Product Development - The company has launched a new electronic medical record system, which is anticipated to increase operational efficiency by 25%[14]. - The company has developed a new core technology, "Large Model Assisted Electronic Medical Record Automatic Generation Technology," which utilizes deep learning to generate structured medical documents, reducing manual input time for doctors[33]. - The company has developed an intelligent, automated, and comprehensive quality control platform for medical records, which aims to enhance the quality control process in hospitals and is currently in the trial operation phase[51]. - The company has completed the development of a smart hospital system, which includes a patient-side app and a doctor-side workstation app, aimed at enhancing communication and service efficiency[52]. - The company is collaborating with its subsidiary to upgrade emergency diagnosis systems, integrating imaging and ultrasound diagnostic products[66]. Financial Management and Risks - The company has recognized a tax reduction to 15% for its subsidiaries recognized as high-tech enterprises, but future changes in tax policies could adversely affect its financial performance[80]. - The company faces risks related to the medical information industry, including potential policy changes that could impact order acquisition and revenue growth stability[81]. - The company has improved its internal control management and cash flow management to strengthen its risk resistance capabilities[62]. - The company reported a negative net cash flow from operating activities of -189.85 million yuan, primarily due to delayed payments from clients and high upfront project investments[78]. Shareholder and Equity Information - The company did not propose any profit distribution or capital reserve fund transfer plans for the half-year period[100]. - The company has committed to a cash dividend policy, ensuring reasonable returns to investors, with specific arrangements for profit distribution outlined in the company's articles of association[121]. - The total number of ordinary shareholders as of the reporting period end was 5,867[146]. - The company’s total share capital was adjusted to 137,570,846 shares after the exercise of stock options and the cancellation of repurchased shares[145]. Environmental and Social Responsibility - The company has implemented green office measures to reduce carbon emissions[108]. - The company is not classified as a key pollutant unit and does not belong to heavily polluting industries[106]. - The company has established an environmental management system and obtained ISO14001:2015 certification[107]. - There were no administrative penalties related to environmental issues during the reporting period[106].

Financial Performance - The company's operating revenue for the third quarter was ¥175,272,087.55, a decrease of 28.68% compared to the same period last year[4]. - The net profit attributable to shareholders was -¥13,787,288.80, representing a decline of 133.47% year-over-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥13,248,115.02, down 132.78% from the previous year[4]. - The net profit attributable to shareholders for the year-to-date period was -¥41,259,537.59, a significant decrease of 328.81% compared to the same period last year[4]. - The company reported a net loss of CNY 72,563,428.01 for the first three quarters of 2024, compared to a loss of CNY 19,149,698.80 in the same period of 2023[21]. - The total profit (loss) for the period was -73,586,781.02 RMB, compared to -19,188,968.02 RMB in the previous period[22]. - The net profit attributable to the parent company's shareholders was -41,259,537.59 RMB, down from 18,032,060.98 RMB year-over-year[23]. - The basic and diluted earnings per share for the third quarter were both -¥0.10, reflecting a decline of 133.33% year-over-year[5]. - The basic and diluted earnings per share were both -0.30 RMB, compared to 0.13 RMB in the same period last year[23]. Research and Development - Research and development expenses totaled ¥56,676,943.62, accounting for 32.34% of operating revenue, an increase of 9.06 percentage points year-over-year[5]. - Research and development expenses for the first three quarters of 2024 amounted to CNY 116,607,510.81, compared to CNY 127,290,711.34 in 2023, indicating a decrease of 8.3%[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,659,989,627.58, a slight increase of 0.54% from the end of the previous year[5]. - Total assets as of September 30, 2024, were CNY 2,659,989,627.58, slightly up from CNY 2,645,633,863.79 at the end of 2023[17]. - Total liabilities increased to CNY 889,967,888.54 as of September 30, 2024, compared to CNY 817,330,281.60 at the end of 2023, marking an increase of 8.8%[17]. - The company's equity attributable to shareholders decreased to CNY 1,773,506,823.62 as of September 30, 2024, down from CNY 1,821,580,993.57 at the end of 2023, a decline of 2.6%[17]. Cash Flow - The company reported a cash flow from operating activities of -¥162,335,536.26 for the year-to-date period[4]. - Cash flow from operating activities generated a net outflow of -162,335,536.26 RMB, an improvement from -226,519,885.58 RMB in the previous year[24]. - Cash inflow from investment activities was 30,477,529.64 RMB, significantly lower than 110,636,068.16 RMB in the prior year[25]. - Cash flow from financing activities resulted in a net inflow of 65,093,607.61 RMB, compared to a net outflow of -54,693,186.32 RMB last year[25]. - The total cash and cash equivalents at the end of the period were 303,496,223.85 RMB, down from 382,650,059.49 RMB at the end of the previous year[25]. - Cash and cash equivalents decreased to CNY 328,568,394.05 as of September 30, 2024, down from CNY 612,478,452.28 at the end of 2023, representing a decline of 46.3%[16]. - The company received 12,878,824.78 RMB in tax refunds, an increase from 8,746,067.31 RMB in the previous year[24]. - The company reported a decrease in cash received from sales of goods and services, totaling 366,295,717.03 RMB, compared to 371,112,264.71 RMB in the same period last year[24]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,576[11]. - The largest shareholder, Xia Jun, holds 24,750,839 shares, representing 17.99% of total shares[11]. - The second largest shareholder, Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, holds 16,812,069 shares, representing 12.22%[11]. - The third largest shareholder, Hongyun Jiukang Data Technology (Beijing) Co., Ltd., holds 11,650,207 shares, representing 8.47%[11]. - The top 10 shareholders collectively hold significant stakes, with the largest three shareholders accounting for 38.68% of total shares[11]. - The company has a total of 4,604,868 shares held by Suzhou Saifu Puxin Medical Health Industry Investment Center, representing 3.35%[12]. - The total number of shares held by the top 10 unrestricted shareholders is 42,000,000 shares[12]. - The company has engaged in margin trading, with specific shares held through this method, including 1,765,000 shares by Beijing Haoqing Wealth Investment Management Co., Ltd.[13]. - The company has not reported any significant changes in shareholder structure due to margin trading activities[14]. Operational Status - There are no other important reminders regarding the company's operational status during the reporting period[14]. - The company did not execute any mergers or acquisitions during the reporting period[26].

Financial Performance - The company's operating revenue for Q3 2023 was CNY 245,755,766.88, representing a year-on-year increase of 20.82%[5] - The net profit attributable to shareholders for Q3 2023 was CNY 41,194,041.14, reflecting a significant increase of 50.95% compared to the same period last year[5] - The basic earnings per share for Q3 2023 was CNY 0.30, up 50.00% from CNY 0.13 in the same quarter last year[6] - The net profit attributable to shareholders for the year-to-date period reached CNY 18,032,060.98, marking a substantial increase of 1,121.77% compared to the same period last year[5] - The diluted earnings per share for the year-to-date period was CNY 0.30, reflecting a 1,200.00% increase from CNY 0.13 in the previous year[6] - Total operating revenue for the first three quarters of 2023 reached ¥537,712,968.92, an increase of 18.1% compared to ¥455,321,747.12 in the same period of 2022[21] - Net profit for the first three quarters of 2023 was ¥1,117,873.06, a significant improvement from a net loss of ¥18,939,625.90 in the same period of 2022[22] - The company reported a basic earnings per share of ¥0.13 for the first three quarters of 2023, compared to ¥0.01 in the same period of 2022[23] Research and Development - Research and development expenses totaled CNY 57,220,973.67 in Q3 2023, which is 23.28% of operating revenue, an increase of 1.01 percentage points year-on-year[6] - Research and development expenses for the first three quarters of 2023 were ¥127,290,711.34, a decrease of 6.5% from ¥135,334,064.77 in the same period of 2022[21] - The company has not disclosed any significant new product or technology developments during the reporting period[16] Cash Flow and Liquidity - The cash flow from operating activities for Q3 2023 was negative at CNY -30,823,444.92, with a year-to-date total of CNY -226,519,885.58[6] - Cash flow from operating activities for the first three quarters of 2023 was ¥371,112,264.71, an increase from ¥346,747,837.31 in the previous year[25] - The net cash flow from operating activities was -226,519,885.58, an improvement from -288,844,282.25 in the previous period[26] - The total cash outflow from operating activities was 633,077,028.10, compared to 690,529,882.61 previously[26] - The company received 100,000,000.00 in cash from investment recoveries[26] - The ending balance of cash and cash equivalents was 382,650,059.49, down from 555,579,181.95 in the previous period[27] Assets and Liabilities - The total assets at the end of Q3 2023 were CNY 2,461,794,791.87, a decrease of 2.61% from the end of the previous year[6] - Total current assets decreased from ¥2,260,656,635.23 at the end of 2022 to ¥2,070,333,698.01, a decline of approximately 8.4%[19] - Non-current assets increased from ¥266,996,990.34 at the end of 2022 to ¥391,461,093.86, an increase of about 46.6%[19] - Total liabilities decreased to ¥614,510,868.05 in 2023 from ¥687,479,956.03 in 2022, reflecting a reduction of approximately 10.6%[20] - Shareholders' equity increased to ¥1,847,283,923.82 in 2023, compared to ¥1,840,173,669.54 in 2022, indicating a slight growth[20] - The total assets and liabilities ratio was approximately 0.97 in 2023, down from 1.00 in 2022, suggesting improved financial stability[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,617[13] - The largest shareholder, Xia Jun, holds 24,750,839 shares, representing 17.88% of total shares[13] Financial Management - The company reported a financial expense of -¥2,495,914.87, an improvement from -¥8,757,501.08 in the previous year, indicating better financial management[21] - The company has invested ¥70,402,293.48 in development expenditures as of September 30, 2023, compared to ¥18,360,179.85 at the end of 2022, an increase of approximately 283.5%[19]

Financial Performance - The net profit attributable to the parent company for 2023 is CNY 32,284,480.94, while the consolidated undistributed profit is CNY -98,076,513.10[4] - The company will not distribute profits for 2023 due to existing undistributed losses and plans to cancel repurchased shares to enhance earnings per share[4] - The company's operating revenue for 2023 was ¥695,175,319.22, a decrease of 3.04% compared to ¥716,948,756.64 in 2022[21] - Net profit attributable to shareholders decreased by 50.01% to ¥32,284,480.94 from ¥64,578,165.82 in the previous year[21] - The net cash flow from operating activities improved by ¥116,115,977.11 compared to the previous year, although it remained negative at -¥143,101,783.01[24] - Basic earnings per share decreased by 51.06% to ¥0.23 from ¥0.47 in 2022[22] - Total assets increased by 4.67% to ¥2,645,633,863.79 at the end of 2023, compared to ¥2,527,653,625.57 at the end of 2022[21] - The weighted average return on equity decreased to 1.78% from 3.65% in the previous year, a decline of 1.87 percentage points[23] Research and Development - Research and development expenses accounted for 32.72% of operating revenue, an increase of 8.01 percentage points from 24.71% in 2022[23] - Research and development investment reached 227.43 million yuan, an increase of 28.38% year-on-year, with 82.50 million yuan capitalized and 144.93 million yuan expensed[33] - The company applied for 40 new invention patents and received authorization for 17 patents during the reporting period, totaling 45 authorized invention patents by the end of the period[34] - The company has developed a medical decision-making engine with a diagnostic accuracy rate exceeding 98% in clinical applications[26] - The company has successfully integrated multiple statistical and machine learning algorithms for risk prediction and analysis in healthcare[28] - The company has accumulated 8 core technologies in smart healthcare, with 34 authorized invention patents and 42 invention patents pending[73] Market Position and Recognition - The company ranked first in the electronic medical record market for the ninth consecutive year, as reported by IDC in July 2023[44] - In 2022, the company held an 8.8% market share in the medical big data sector, ranking first in China for the fourth consecutive year[45] - The company was recognized as one of the top 50 most influential enterprises in medical health information technology in 2023[45] - The company ranks first in the Chinese medical big data solution market in 2022, as reported by IDC[72] - The company has established a nationwide marketing network with over 1,600 clients, reflecting a strong brand presence and customer loyalty[107] Corporate Governance - The company has not disclosed any special arrangements for corporate governance[7] - The company strictly adheres to the regulations of the Company Law, Securities Law, and the Shanghai Stock Exchange's listing rules, ensuring a well-structured governance framework[161] - The governance structure is continuously improved to align with regulatory requirements, ensuring compliance and operational integrity[161] - The company has implemented stock incentive plans for key personnel, with notable increases in shareholdings for several executives, such as Ren Yong, who received 135.90 thousand yuan in remuneration[166] Strategic Initiatives and Future Outlook - The company is focusing on the integration of high-quality medical data management, driven by policies promoting the development of public hospitals[37] - The company is actively exploring the development of AI technologies to enhance existing products, particularly in the field of medical data utilization[34] - The company plans to invest in the development of specialized electronic medical records and clinical research products based on AI and big data technologies, aiming to improve the quality and efficiency of core business in medical institutions[157] - The company aims to become a leading enterprise in the domestic medical information industry, focusing on clinical information construction and following the development path of "informationization - digitalization - intelligentization"[154] Challenges and Risks - The management has highlighted potential risks in the future plans and development strategies, cautioning investors about uncertainties[5] - The company faces risks related to market competition and the need for continuous technological upgrades to maintain its competitive advantage[109] - The company is exposed to risks from changes in tax incentives, which could increase tax liabilities and negatively impact financial performance[115] - The company faced risks related to weak receivables collection, particularly from medical institutions, which could adversely affect cash flow and operational performance[112] Employee and Talent Development - The number of R&D personnel increased to 705, representing 34.39% of the total workforce, compared to 34.96% in the previous period[99] - The company has established a comprehensive professional training system to enhance employee skills and management capabilities[192] - The company is committed to establishing a talent introduction and incentive mechanism to improve employee loyalty and attract high-quality external experts[158] Technology and Innovation - The integration of new technologies such as big data, AI, cloud computing, and IoT is revolutionizing the efficiency and effectiveness of the healthcare industry[68] - The company has developed a smart medical data platform that processes and analyzes large-scale heterogeneous medical data, enhancing patient services and clinical decision support[73] - The technology for automatic generation of medical records supports over 1,100 specialty diagnoses and includes more than 400 treatment plans and 1,700 specialty medical record templates[76] Financial Management - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 6.061 million RMB[175] - The total remuneration for core technical personnel at the end of the reporting period was 3.9966 million RMB[176] - The company has a clear salary policy based on fairness, competitiveness, and performance, ensuring timely payment of wages[190]

Financial Performance - In 2024, the company reported a revenue of 591.94 million yuan, a decrease of 14.85% compared to 2023 [1][2] - The net profit attributable to shareholders was -256.12 million yuan, down from a profit of 32.28 million yuan in the previous year [1][2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -261.38 million yuan, compared to 25.45 million yuan in 2023, marking a decline of 1,126.89% [1][2] - The net cash flow from operating activities was -67.63 million yuan [1][2] Q1 2025 Performance - For the first quarter of 2025, the company achieved a revenue of 101 million yuan, a year-on-year decline of 17.43% [1][2] - The net profit attributable to shareholders for Q1 2025 was -17.43 million yuan, compared to -11.85 million yuan in the same period last year [1][2] - The net profit after deducting non-recurring gains and losses was -17.96 million yuan, down from -13.03 million yuan in Q1 2024 [1][2] - The net cash flow from operating activities for Q1 2025 was -94.06 million yuan [1][2] Company Background - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 14, 2021, with an initial offering price of 39.50 yuan per share [4] - The total funds raised from the initial public offering amounted to 1.362 billion yuan, with a net amount of 1.24 billion yuan after deducting issuance costs [4] - The company planned to use the raised funds for various projects, including the development of specialized electronic medical records and upgrading data centers [4]

中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址：北京市丰台区丽泽路 20 号丽泽 SOHO Ｂ座 20 层 邮编：100073 电话：(010) 51423818 传真：(010) 51423816 嘉和美康(北京)科技股份有限公司 2024年度合并及母公司财务报表 审计报告书 目 录 一、审计报告 二、审计报告附送 1. 合并及母公司资产负债表 2. 合并及母公司利润表 3. 合并及母公司现金流量表 4. 合并股东权益变动表 5. 母公司股东权益变动表 6. 财务报表附注 三、审计报告附件 1. 中兴华会计师事务所（特殊普通合伙）营业执照复印件 2. 中兴华会计师事务所（特殊普通合伙）执业证书复印件 3. 注册会计师执业证书复印件 中兴华会计师事务所（特殊普通合伙） 中 兴 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） Z H O N G X I N G H U A C E R T I F I E D P U B L I C A C C O U N T A N T S L L P 地 址 （ l o c a ...

一、计提减值准备的情况概述 证券代码：688246 证券简称：嘉和美康 公告编号：2025-033 嘉和美康（北京）科技股份有限公司 关于 2024 年年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一）信用减值损失 公司以预期信用损失为基础，对应收票据、应收账款、其他应收款进行了减 值测试。经测试，本次需计提信用减值损失金额共计 5,418.77 万元。 嘉和美康（北京）科技股份有限公司（以下简称"公司"）根据《企业会计 准则第 8 号——资产减值》（以下简称"《企业会计准则》"）和相关会计政策的规 定，结合公司的实际情况，为客观、公允地反映公司截至 2024 年 12 月 31 日的 财务状况和 2024 年 1-12 月的经营成果，公司对截至 2024 年 12 月 31 日合并范 围内存在减值迹象的资产进行了减值测试并计提了相应的减值准备。公司 2024 年 1-12 月计提各类信用减值损失及资产减值损失共计人民币 11,874.16 万元， 具体情况如下： 单位：人民币万元 项目 2 ...

嘉和美康(北京)科技股份有限公司 关于 2024 年度"提质增效重回报行动方案"的年度 评估报告 嘉和美康(北京)科技股份有限公司（以下简称"公司"）为践行"以投资者 为本"的上市公司发展理念，维护公司全体股东利益，增强投资者信心，促进公 司长远健康可持续发展，基于对公司未来发展前景的信心和对公司价值的认可， 公司于 2024 年 7 月 17 日发布了 2024 年度"提质增效重回报"行动方案。 本公司始终坚守以投资者利益为核心的原则，通过不断深化主营业务，提升 公司业绩，稳固在行业中的领先地位，积极传递公司价值等多种方式提振投资者 信心。现将 2024 年度"提质增效重回报"行动方案的实施和效果评估情况报告 如下： 一、聚焦主业发展，持续优化产品品类，完善产品布局 2024 年，公司坚持以市场需求为导向，将医疗大数据、人工智能、云计算、 区块链以及 5G 等先进技术，全方位应用于医院的"医-教-研-管"全链条，打造 全场景智慧医院，引领医疗革新，重塑新质生产力，推动医院高质量发展。 1. 丰富智慧临床产品，临床业务和临床管理双维度同步推进 推出中枢化决策支持引擎及医疗 AI 应用开放平台，打造全院级智慧服 ...

证券代码：688246 证券简称：嘉和美康 公告编号：2025-028 嘉和美康（北京）科技股份有限公司 关于未弥补亏损达到实收股本三分之一的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 嘉和美康（北京）科技股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日召开第四届董事会第二十五次会议，审议通过了《关于公司未弥补亏损达 到实收股本三分之一的议案》。根据中兴华会计师事务所（特殊普通合伙）为公 司出具的标准无保留意见的审计报告。截至 2024 年 12 月 31 日，公司合并财务 报表（经审计）未分配利润为-35,419.39 万元，公司股本总额为 13,758.56 万 元，未弥补亏损金额已达到实收股本总额的三分之一。根据《中华人民共和国公 司法》及《公司章程》的有关规定，公司未弥补的亏损达到实收股本总额三分之 一，本议案尚需提交至公司 2024 年年度股东大会审议。 一、主要原因 公司未弥补亏损超过实收股本总额的三分之一，主要系公司 （1）收入及成本的影响 报告期内，受整体经济环境及医疗行业环境的 ...

嘉和美康（北京）科技股份有限公司 2024 年度会计师事务所履职情况评估报告 嘉和美康（北京）科技股份有限公司（以下简称"公司"）聘请中兴华会计 师事务所（特殊普通合伙）（以下简称"中兴华会计事务所"）作为公司 2024 年度财务报表及内部控制审计机构。根据财政部、国资委及证监会颁布的《国有 企业、上市公司选聘会计师事务所管理办法》，公司对中兴华会计师事务所 2024 年审计过程中的履职情况进行评估。 经评估，公司认为中兴华会计师事务所资质等方面合规有效，履职保持独立 性，勤勉尽责，公允表达意见，具体情况如下： 一、2024 年年审会计师事务所基本情况 （一）机构信息 1.基本信息 （1）机构名称：中兴华会计师事务所（特殊普通合伙） （2）成立日期：2013 年 11 月 4 日（由中兴华会计师事务所有限责任公司 转制为特殊普通合伙企业） （3）组织形式：特殊普通合伙 （4）注册地址：北京市丰台区丽泽路 20 号院 1 号楼南楼 20 层 （5）首席合伙人：李尊农 （6）人员信息：截至 2024 年 12 月 31 日，合伙人数 199 名，注册会计师人 数 1052 名，签署过证券服务业务审计报告的注册会计 ...